Overview
- Adjusted earnings reached $1.89 per share on revenue of $6.05 billion, topping estimates of $1.72 and $6.01 billion, respectively.
- Shares rose about 7% to 8% intraday following the results, according to market data cited in the coverage.
- Management kept full-year guidance at $7.70 to $7.80 in adjusted EPS and projected low-single-digit core revenue growth for 2025.
- Operating cash flow totaled roughly $1.7 billion and adjusted free cash flow was about $1.4 billion for the quarter.
- Biotech/bioprocessing grew 6.5% organically and diagnostics rose 3.5%, while life sciences declined about 1% and missed Street expectations.